Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.86 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.86 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.86 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.86 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.86 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.86 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.86 |
| ▸ | CACNA1C | Q13936 | 4/20 | 0.86 |
| ▸ | LMNA | P02545 | 4/20 | 0.86 |
| ▸ | CACNA1D | Q01668 | 4/20 | 0.86 |
| ▸ | MAPT | P10636 | 4/20 | 0.86 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.86 |
| ▸ | SCN1A | P35498 | 3/20 | 0.86 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.86 |
| ▸ | SCN2A | Q99250 | 3/20 | 0.86 |
| ▸ | SCN3A | Q9NY46 | 3/20 | 0.86 |
| ▸ | CACNA1F | O60840 | 3/20 | 0.86 |
| ▸ | CACNA1S | Q13698 | 3/20 | 0.86 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.86 |
| ▸ | TSHR | P16473 | 3/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1617472 | 0.95 | CACNA1C (0.77) | ADORA3CYP1A2HIF1ACYP2C9CYP3A4 | |
| SCHEMBL29810716 | 0.95 | CACNA1C (0.77) | ADORA3CYP1A2HIF1ACYP2C9CYP3A4 | |
| SCHEMBL11689121 | 0.93 | ADORA3 (0.75) | ADORA3CYP1A2HIF1ACYP2C9CYP3A4 | |
| Nifedipine SCHEMBL2156554 | 0.93 | ADORA3 (0.90) | ADORA3CYP1A2HIF1ACYP2C9CYP3A4 | |
| Nifedipine SCHEMBL3968 | 0.93 | ADORA3 (1.00) | ADORA3CYP1A2HIF1ACYP2C9CYP3A4 | |
| Nifedipine SCHEMBL1172946 | 0.93 | ADORA3 (1.00) | ADORA3CYP1A2HIF1ACYP2C9CYP3A4 | |
| Nifedipine SCHEMBL29349595 | 0.93 | ADORA3 (1.00) | ADORA3CYP1A2HIF1ACYP2C9CYP3A4 | |
| SCHEMBL7158381 | 0.92 | ADORA3 (0.80) | ADORA3CYP1A2HIF1ACYP2C9CYP3A4 | |
| SCHEMBL10742853 | 0.92 | ADORA3 (0.72) | ADORA3CYP1A2HIF1ACYP2C9CYP3A4 | |
| Nifedipine SCHEMBL8851402 | 0.92 | ADORA3 (0.97) | ADORA3CYP1A2HIF1ACYP2C9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008091135-A1 | CONDUCTIVE POLYMER COMPOSITION FOR RADIOGRAPHIC IMAGING | ELPANI CO., LTD. (KR) | 2008-07-31 | — | — | WO | claimed |
| US-6545028-B2 | Antiepileptic agents, hypotensive agents; monitoring membrane potentials | NEUROSEARCH A/S (DK) | 2003-04-08 | — | — | US | claimed |
| US-20020119989-A1 | Chemical compounds having ion channel blocking activity for the treatment of immune dysfunction | ANIONA APS (DK) | 2002-08-29 | — | — | US | claimed |
| WO-2008091135-A1 | CONDUCTIVE POLYMER COMPOSITION FOR RADIOGRAPHIC IMAGING | ELPANI CO., LTD. (KR) | 2008-07-31 | — | — | WO | disclosed |
| EP-1528960-A1 | MULTILAYER COATING SYSTEM COMPRISING THIOL-FUNCTIONAL COMPOUNDS | Akzo Nobel Coatings International B.V. (NL) | 2005-05-11 | — | — | EP | disclosed |
| WO-2004018115-A1 | MULTILAYER COATING SYSTEM COMPRISING THIOL-FUNCTIONAL COMPOUNDS | AKZO NOBEL COATINGS INTERNATIONAL B.V. (NL) | 2004-03-04 | — | — | WO | disclosed |
| US-20030230478-A1 | Process for the preparation of 1,4 - dihydropyridines and novel 1,4-dihydropyridines useful as therapeutic agents | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH | 2003-12-18 | — | — | US | disclosed |
| WO-2003099790-A1 | PROCESS FOR THE PREPARATION OF 1,4-DIHYDROPYRIDINES AND NOVEL 1,4-DIHYDROPYRIDINES USEFUL AS THERAPEUTIC AGENTS | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2003-12-04 | — | — | WO | disclosed |
| US-6545028-B2 | Antiepileptic agents, hypotensive agents; monitoring membrane potentials | NEUROSEARCH A/S (DK) | 2003-04-08 | — | — | US | disclosed |
| US-20020119989-A1 | Chemical compounds having ion channel blocking activity for the treatment of immune dysfunction | ANIONA APS (DK) | 2002-08-29 | — | — | US | disclosed |
| US-6067135-A | Liquid crystal display device and method of manufacturing the same | KABUSHIKI KAISHA TOSHIBA (JP) | 2000-05-23 | — | — | US | disclosed |
| US-4988717-A | Optically active 1,4-dihydropyridine esters useful for treating circulatory illnesses | BAYER AKTIENGESELLSCHAFT (DE) | 1991-01-29 | — | — | US | disclosed |
| US-4849433-A | The compound, (⃡)1,4-dihydro-2,6-dimethyl-4-(2'-nitrophenyl)-pyridine-3,5-dicarboxylic acid, methyl isobutyl ester, compositions containing same and a method for effecting coronary dilation | BAYER AKTIENGESELLSCHAFT (DE) | 1989-07-18 | — | — | US | disclosed |
| US-4510310-A | 1,4-Dihydro-2,6-dimethyl-4-(2'-chlorophenyl)-3,5-dicarboxylic acid,methyl or ethyl,trifluoroethyl ester | BAYER AKTIENGESELLSCHAFT (DE) | 1985-04-09 | — | — | US | disclosed |
| US-3932645-A | CORONARY VASODILATORS, HYPOTENSIVE AGENTS | FARBENFABRIKEN BAYER AG (DT) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030230478-A1 | Process for the preparation of 1,4 - dihydropyridines and novel 1,4-dihydropyridines useful as therapeutic agents | HRH4, ODC1, OGDH | ADORA3 238/4885CYP1A2 214/4885HIF1A 152/4885 |
| US-20020119989-A1 | Chemical compounds having ion channel blocking activity for the treatment of immune dysfunction | KCNN2, KCNN1, KCNJ2 | ADORA3 1409/4885CYP1A2 3170/4885HIF1A 2396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.